MASAŘÍK, Michal, Jaromír GUMULEC, Marián HLAVNA, Markéta SZTALMACHOVÁ, Petr BABULA, Vojtěch ADAM, Soňa KŘÍŽKOVÁ, Roman HRABEC, Arne ROVNÝ and René KIZEK. Analysis of tumor markers in prostate carcinoma at RNA and protein level. In 16th World Congress on Advances in Oncology, 14th Internation Symposium on Molecular Medicine. 2011. ISSN 1107-3756.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Analysis of tumor markers in prostate carcinoma at RNA and protein level
Name in Czech Analýza nádorových markerů karcinomu prostaty na úrovni RNA a proteinu
Authors MASAŘÍK, Michal, Jaromír GUMULEC, Marián HLAVNA, Markéta SZTALMACHOVÁ, Petr BABULA, Vojtěch ADAM, Soňa KŘÍŽKOVÁ, Roman HRABEC, Arne ROVNÝ and René KIZEK.
Edition 16th World Congress on Advances in Oncology, 14th Internation Symposium on Molecular Medicine, 2011.
Other information
Original language English
Type of outcome Conference abstract
Field of Study 30200 3.2 Clinical medicine
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 1.573
Organization unit Faculty of Medicine
ISSN 1107-3756
UT WoS 000295422700165
Changed by Changed by: doc. MUDr. Jaromír Gumulec, Ph.D., učo 185198. Changed: 14/2/2012 19:25.
Abstract
Prostate carcinoma belongs to group of diseases with high risk of death. The incidence of this pathology is closely connected with higher age and 90% of all cases represent acinar adenocarcinoma. In this study, we focus on the differences in gene expression between tumor and non-tumor cell lines and differences in protein spectrum in serum samples of patients and control individuals. Cell lines were represented by 22Rv1 derived from androgen-dependent primary tumor from patient with bone metastases and PNT1A, immortalized line derived from normal prostatic epitheliu. We determined a level of RNA using the TaqMan gene expression assay and analysed by the comparative Ct method using b-actin. We focused on these genes: Metallothionein 1A and 2A, prostate specific antigen, alpha methylacyl-CoA racemase (AMACR) and Caveolin-1. Using electrochemical detection and ELISA technique we determined metallothionein, AMACR and caveolin-1 in cell lysates and in serum samples of patients and controls. We found significant down regulation in expression of cav-1 gene on the other hand we observed significant up regulation in expression of PSA, metallothionein 1A, 2A and AMACR in tumor cell line 22Rv1. At protein level we found significant accumulation of metallothionein in serum samples of prostate carcinoma patients.
Links
GP301/09/P436, research and development projectName: Analýza metalothioneinu u karcinomu prostaty na úrovni DNA, RNA a proteinu.
Investor: Czech Science Foundation
PrintDisplayed: 29/7/2024 22:17